Sandostatin Lar 10 mg Powder For Suspension, Sustained-Release is a Health Canada–registered human drug (DIN 02239323) held by Novartis Pharmaceuticals Canada Inc, containing Octreotide (Octreotide Acetate). Health Canada lists its status as Marketed (status date 27 Jan 1999). Nexara Health has matched 386 registrations of Octreotide (Octreotide Acetate) across 33 other regulated markets.
Health Canada registration
| DIN | 02239323 |
|---|---|
| Brand name | Sandostatin Lar |
| Active ingredient | Octreotide (Octreotide Acetate) |
| Strength | 10 mg |
| Dosage form | Powder For Suspension, Sustained-Release |
| Route | Intramuscular |
| Company | Novartis Pharmaceuticals Canada Inc |
| Status | Marketed — 27 Jan 1999 |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H01CB02 OCTREOTIDE |
| AHFS | 92:00.00 |
| Original market date | 27-Jan-1999 |
| Regulator record | Health Canada DPD entry · Product monograph |
Octreotide (Octreotide Acetate) registered in other markets
386 registrations of the same molecule in 33 national registries outside Canada (first 120 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Australia | Octreotide (SUN) | Ra | Injection 500 micrograms (as acetate) in 1 mL | HS | PBS | |
| Australia | Octreotide GH | Hq | Injection 50 micrograms (as acetate) in 1 mL | HS | PBS | |
| Australia | Sandostatin 0.05 | NV | Injection 50 micrograms (as acetate) in 1 mL | HB | PBS | |
| Australia | Sandostatin 0.1 | NV | Injection 100 micrograms (as acetate) in 1 mL | HS | PBS | |
| Australia | Sandostatin 0.1 | NV | Injection 100 micrograms (as acetate) in 1 mL | HB | PBS | |
| Australia | Sandostatin 0.5 | NV | Injection 500 micrograms (as acetate) in 1 mL | HB | PBS | |
| Australia | Sandostatin LAR | NV | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | CA | PBS | |
| Australia | Sandostatin LAR | NV | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | HB | PBS | |
| Austria | Sandostatin 100 mcg/ml Inj.-/Inf.lsg. | — | 5St | yellow box | eEKO (Erstattungskodex) | |
| Austria | Sandostatin 50 mcg/ml Inj.-/Inf.lsg. | — | 5St | yellow box | eEKO (Erstattungskodex) | |
| Austria | Sandostatin 500 mcg/ml Inj.-/Inf.lsg. | — | 5St | yellow box | eEKO (Erstattungskodex) | |
| Austria | Sandostatin LAR 10 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | — | 1St | green box | eEKO (Erstattungskodex) | |
| Austria | Sandostatin LAR 20 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | — | 1St | green box | eEKO (Erstattungskodex) | |
| Austria | Sandostatin LAR 30 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | — | 1St | green box | eEKO (Erstattungskodex) | |
| Bahrain | Sandostatin | Novartis Pharma AG, Switzerland. | 0.1 MG/ML | Solution For Injection/Infusion | POM | NHRA |
| Bahrain | Sandostatin Lar | Novartis Pharma AG, Switzerland. | 20 MG | Powder And Solvent For Suspension For Injection | POM | NHRA |
| Bahrain | Syngro | Jazeera Pharmaceuticals Industries, Ksa. | 30 MG | Powder And Solvent For Suspension For Injection | POM | NHRA |
| Bahrain | Syngro | Jazeera Pharmaceuticals Industries, Ksa. | 20 MG | Powder And Solvent For Suspension For Injection | POM | NHRA |
| Bulgaria | Octreotide LAI Teva | Teva B.V. | 20 mg powder and solvent for prolonged-release suspension for injection | прах и разтворител за суспензия за инжекции | По лекарско предписание | BDA |
| Bulgaria | Octreotide LAI Teva | Teva B.V. | 30 mg powder and solvent for prolonged-release suspension for injection | прах и разтворител за суспензия за инжекции | По лекарско предписание | BDA |
| Bulgaria | Octreotide Lyomark | Lyomark Pharma GmbH | 0,1 mg/ml solution for injection | инжекционен разтвор | По лекарско предписание | BDA |
| Bulgaria | Octreotide Rompharm | S.c. Rompharm Company S.r.l. | 0,1 mg/1 ml solution for injection/infusion 1 PVC foil upports with 3 ampoules | инжекционен разтвор | По лекарско предписание | BDA |
| Bulgaria | Sandostatin | Novartis Europharm Limited | 100 microgram/1 ml solution for injection/infusion | инжекционен разтвор | По лекарско предписание | BDA |
| Bulgaria | Sandostatin LAR | Novartis Europharm Limited | 20 mg powder and solvent for suspension for injection | прах и разтворител за суспензия за инжекции | По лекарско предписание | BDA |
| Bulgaria | Sandostatin LAR | Novartis Europharm Limited | 30 mg powder and solvent for suspension for injection | прах и разтворител за суспензия за инжекции | По лекарско предписание | BDA |
| Croatia | Oktreotid Teva | Teva B.V. | boč. 1x30 mg | HZZO | ||
| Croatia | Oktreotid Teva | Teva B.V. | boč. 1x20 mg | HZZO | ||
| Croatia | Sandostatin | Novartis Hrvatska d.o.o. | amp. 5x0,50 mg | HZZO | ||
| Croatia | Sandostatin | Novartis Hrvatska d.o.o. | amp. 5x0,10 mg | HZZO | ||
| Croatia | Sandostatin Lar | Novartis Hrvatska d.o.o. | boč. 1x30 mg | HZZO | ||
| Croatia | Sandostatin Lar | Novartis Hrvatska d.o.o. | boč. 1x20 mg | HZZO | ||
| Czech Republic | Octreotide Teva | — | 20MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Octreotide Teva | — | 10MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Octreotide Teva | — | 30MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Octreotide Teva B. V. | — | 20MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Octreotide Teva B. V. | — | 30MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Octreotide Teva B. V. | — | 10MG | Inj Plq Sus Pro | R | SUKL DLP |
| Czech Republic | Oczyesa | — | 20MG | Inj Sol Pro Pep | R | SUKL DLP |
| Czech Republic | Okrodin | — | 20MG | Inj Plq Sus Pro | R | SUKL DLP |
| Denmark | Mycapssa | Amryt Pharmaceuticals DAC | 20 mg | enterokapsler, hårde | Central | Laegemiddelstyrelsen |
| Denmark | Octreoanne | Teva B.V. | 10 mg | pulver og solvens til depotinjektionsvæske, suspension | Decentral procedure | Laegemiddelstyrelsen |
| Denmark | Octreoanne | Teva B.V. | 20 mg | pulver og solvens til depotinjektionsvæske, suspension | Decentral procedure | Laegemiddelstyrelsen |
| Denmark | Octreoanne | Teva B.V. | 30 mg | pulver og solvens til depotinjektionsvæske, suspension | Decentral procedure | Laegemiddelstyrelsen |
| Denmark | Octreotid "Sun" | SUN Pharmaceutical Industries Europe BV | 0,05 mg/1 ml | injektionsvæske, opløsning | MRP | Laegemiddelstyrelsen |
| Denmark | Octreotid "Sun" | SUN Pharmaceutical Industries Europe BV | 1 mg/5 ml | injektionsvæske, opløsning | MRP | Laegemiddelstyrelsen |
| Denmark | Octreotid "Sun" | SUN Pharmaceutical Industries Europe BV | 0,1 mg/1 ml | injektionsvæske, opløsning | MRP | Laegemiddelstyrelsen |
| Denmark | Octreotid "Sun" | SUN Pharmaceutical Industries Europe BV | 0,5 mg/1 ml | injektionsvæske, opløsning | MRP | Laegemiddelstyrelsen |
| European Union (EMA) | Mycapssa | Amryt Pharmaceuticals DAC | Withdrawn | EMA centrally authorised | ||
| European Union (EMA) | Oczyesa | Camurus AB | Authorised | EMA centrally authorised | ||
| Finland | Mycapssa | Amryt Pharmaceuticals DAC | 20 mg | enterokapseli, kova | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Finland | Octreotide Pfizer | Hospira UK Ltd. | 50 mikrog/ml | injektioneste, liuos | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Finland | Octreotide Pfizer | Hospira UK Ltd. | 200 mikrog/ml | injektioneste, liuos | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Finland | Octreotide Pfizer | Hospira UK Ltd. | 500 mikrog/ml | injektioneste, liuos | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Finland | Octreotide Pfizer | Hospira UK Ltd. | 100 mikrog/ml | injektioneste, liuos | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Finland | Octreotide ratiopharm | Teva B.V. | 10 mg | injektiokuiva-aine ja liuotin, depotsuspensiota varten | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Finland | Octreotide ratiopharm | Teva B.V. | 20 mg | injektiokuiva-aine ja liuotin, depotsuspensiota varten | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Finland | Octreotide ratiopharm | Orifarm Oy | 30 mg | injektiokuiva-aine ja liuotin, depotsuspensiota varten | Myyntilupa peruuntunut | Fimea Perusrekisteri |
| Greece | Okrodin® Pd.s.in.pr 10mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | Φαρματεν Αβεε | reimbursed | MoH deltio timwn | ||
| Greece | Okrodin® Pd.s.in.pr 20mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | Φαρματεν Αβεε | reimbursed | MoH deltio timwn | ||
| Greece | Okrodin® Pd.s.in.pr 30mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | Φαρματεν Αβεε | reimbursed | MoH deltio timwn | ||
| Greece | SANDOSTATIN INJ.SO.INF 0,1MG/ML AMP BTx5 AMP | Novartis (Hellas) A.e.b.e. | reimbursed | MoH deltio timwn | ||
| Greece | SANDOSTATIN INJ.SO.INF 0,5MG/ML AMP BT x 5 AMP x 1ML | Novartis (Hellas) A.e.b.e. | reimbursed | MoH deltio timwn | ||
| Greece | SANDOSTATIN LAR PS.INJ.SUS 10MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | Novartis (Hellas) A.e.b.e. | reimbursed | MoH deltio timwn | ||
| Greece | SANDOSTATIN LAR PS.INJ.SUS 20MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | Novartis (Hellas) A.e.b.e. | reimbursed | MoH deltio timwn | ||
| Greece | SANDOSTATIN LAR PS.INJ.SUS 30MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου x 2,5 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | Novartis (Hellas) A.e.b.e. | reimbursed | MoH deltio timwn | ||
| Iceland | Octreotid | Vistor - óskráð | 100 mcg/ml | stl | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Sandostatin | Novartis Healthcare A/S | 100 mcg/ml | stl | 1 | Lyfjastofnun lyfjaverdskra |
| Iceland | Sandostatin | Novartis Healthcare A/S | 50 mcg/ml | stl | 1 | Lyfjastofnun lyfjaverdskra |
| Iceland | Sandostatin Lar | Novartis Healthcare A/S | 30 mg | sts | 1 | Lyfjastofnun lyfjaverdskra |
| Iceland | Sandostatin Lar | Novartis Healthcare A/S | 20 mg | sts | 1 | Lyfjastofnun lyfjaverdskra |
| Iceland | Sandostatin Lar | Novartis Healthcare A/S | 10 mg | sts | 1 | Lyfjastofnun lyfjaverdskra |
| Ireland | Octreotide 100 micrograms/1 ml solution for injection | Pfizer Healthcare Ireland Unlimited Company | Solution for injection | Marketed | HPRA | |
| Ireland | Octreotide 50 micrograms/1 ml solution for injection | Pfizer Healthcare Ireland Unlimited Company | Solution for injection | Not marketed | HPRA | |
| Ireland | Octreotide 500 micrograms/1 ml solution for injection | Pfizer Healthcare Ireland Unlimited Company | Solution for injection | Marketed | HPRA | |
| Ireland | Oczyesa 20 mg prolonged-release solution for injection in pre-filled pen | Camurus AB | Prolonged-release solution for injection | Unknown | HPRA | |
| Ireland | Olatuton 10 mg powder and solvent for prolonged-release suspension for injection | Teva B.V. | Powder and solvent for prolonged-release suspension for injection | Not marketed | HPRA | |
| Ireland | Olatuton 20 mg powder and solvent for prolonged-release suspension for injection | Teva B.V. | Powder and solvent for prolonged-release suspension for injection | Not marketed | HPRA | |
| Ireland | Olatuton 30 mg powder and solvent for prolonged-release suspension for injection | Teva B.V. | Powder and solvent for prolonged-release suspension for injection | Not marketed | HPRA | |
| Ireland | SANDOSTATIN 100 microgram/1ml, solution for injection/infusion | Novartis Ireland Limited | Solution for injection/infusion | Marketed | HPRA | |
| Italy | OCTREOTIDE*1 flaconcino SC 1 mg 5 ml | Sun Pharmaceutical Ind.eu.b.v. | OCTREOTIDE 1MG 1 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*1 flaconcino SC EV 5 ml 1 mg/5 ml | BIOINDUSTRIA L.I.M. SpA | OCTREOTIDE 1MG 1 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 10 mg + 1 siringa solv 2 ml + adattatore + ago | Teva B.v. | OCTREOTIDE 10MG 1 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 20 mg + 1 siringa solv 2 ml + adattatore + ago | Teva B.v. | OCTREOTIDE 20MG 1 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 30 mg + 1 siringa solv 2 ml + adattatore + ago | Teva B.v. | OCTREOTIDE 30MG 1 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,05 mg/ml | BIOINDUSTRIA L.I.M. SpA | OCTREOTIDE 0,05MG 10 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,1 mg/ml | BIOINDUSTRIA L.I.M. SpA | OCTREOTIDE 0,1MG 10 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,5 mg/ml | BIOINDUSTRIA L.I.M. SpA | OCTREOTIDE 0,5MG 10 UNITA' USO PARENTERALE | Classe A | AIFA liste A/H | |
| Luxembourg | Sandostatine Long Acting Repeatable PSV.SP.INJ. 20 mg 1*1 flacon poudre + 1*1 ser.prer.solvant | — | RR | CNS liste positive | ||
| Luxembourg | Sandostatine Long Acting Repeatable PSV.SP.INJ. 30 mg 1*1 flacon poudre + 1*1 ser.prer.solvant | — | RR | CNS liste positive | ||
| Luxembourg | Sandostatine SOL.INJ. 0,5 mg / 1 mL 1*10 ampoules 1 mL | — | RR | CNS liste positive | ||
| MA | Sandostatine * | — | 100 µG | Solution Injectable | P | CNOPS liste des medicaments |
| MA | Sandostatine * | — | 50 µG | Solution Injectable | P | CNOPS liste des medicaments |
| MA | Sandostatine * | — | 500 µG | Solution Injectable | P | CNOPS liste des medicaments |
| Malaysia | Sandostatin Ampoules 0.05 mg/1 mL | Novartis Corporation (Malaysia) Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Sandostatin Ampoules 0.1mg/1 mL | Novartis Corporation (Malaysia) Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Sandostatin Lar 20mg | Novartis Corporation (Malaysia) Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malaysia | Sandostatin Lar 30mg | Novartis Corporation (Malaysia) Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malta | Olatuton 10mg Powder and Solvent for Prolonged-Release Suspension for Injection | Central Procurement & Supplies Unit | Powder And Solvent For Prolonged-Release Suspension For Injection | Authorised | Medicines Authority | |
| Malta | Olatuton 30mg Powder and Solvent for Prolonged-Release Suspension for Injection | Central Procurement & Supplies Unit | Powder And Suspension For Suspension For Injection | Authorised | Medicines Authority | |
| Malta | SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection | Novartis Ireland Limited | Powder And Solvent For Suspension For Injection | Authorised | Medicines Authority | |
| Malta | SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection | Novartis Ireland Limited | Powder And Solvent For Suspension For Injection | Authorised | Medicines Authority | |
| Malta | SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection | Novartis Ireland Limited | Powder And Solvent For Suspension For Injection | Authorised | Medicines Authority | |
| Netherlands | Octreotide Bendalis 0,05 mg/ml, oplossing voor injectie | Bendalis GmbH | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide Bendalis 0,1 mg/ml, oplossing voor injectie | Bendalis GmbH | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide Bendalis 0,2 mg/ml, oplossing voor injectie | Bendalis GmbH | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide Bendalis 0,5 mg/ml, oplossing voor injectie | Bendalis GmbH | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide depot Teva 10 mg, poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Teva B.V. | Poeder en oplosmiddel voor suspensie voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide depot Teva 20 mg, poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Teva B.V. | Poeder en oplosmiddel voor suspensie voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide depot Teva 30 mg, poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Teva B.V. | Poeder en oplosmiddel voor suspensie voor injectie | Uitsluitend recept | EU national register | |
| Netherlands | Octreotide Medcor 0,05 mg/ml oplossing voor injectie in een voorgevulde spuit | Medcor Pharmaceuticals B.V. | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Norway | Octreotid bendalis inj/inf, oppl 0,2 mg/ml | Bendalis | 10 x 5 | Injeksjons-/infusjonsvæske, oppløsning | Aktiv oppføring | FEST (DMP) |
| Norway | Octreotide Acetate avet inj, oppl 5000 mikrog/5 ml | Avet Pharmaceuticals | 5 | Injeksjonsvæske, oppløsning | Aktiv oppføring | FEST (DMP) |
| Norway | Sandostatin inj/inf, oppl 100 mikrog/ml | Novartis Norge (2) | 5 x 1 | Injeksjons-/infusjonsvæske, oppløsning | Aktiv oppføring | FEST (DMP) |
| Norway | Sandostatin inj/inf, oppl 50 mikrog/ml | Novartis Norge (2) | 5 x 1 | Injeksjons-/infusjonsvæske, oppløsning | Aktiv oppføring | FEST (DMP) |
| Norway | Sandostatin LAR pulv+væske til inj susp 10 mg | Novartis Norge (2) | 1 | Pulver og væske til injeksjonsvæske, suspensjon | Aktiv oppføring | FEST (DMP) |
| Norway | Sandostatin LAR pulv+væske til inj susp 20 mg | Novartis Norge (2) | 1 | Pulver og væske til injeksjonsvæske, suspensjon | Aktiv oppføring | FEST (DMP) |
| Norway | Sandostatin LAR pulv+væske til inj susp 30 mg | Novartis Norge (2) | 1 | Pulver og væske til injeksjonsvæske, suspensjon | Aktiv oppføring | FEST (DMP) |
| Poland | Okteva | Teva B.V. | 20 mg | Proszek i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań o przedłużonym uwalnianiu | Bezterminowe | URPL RPL |
| Poland | Sandostatin | Novartis Poland Sp. z o.o. | 100 mcg/ml | Roztwór do wstrzykiwań / do infuzji | Bezterminowe | URPL RPL |
| Poland | Sandostatin | Novartis Poland Sp. z o.o. | 50 mcg/ml | Roztwór do wstrzykiwań / do infuzji | Bezterminowe | URPL RPL |
See every manufacturer of Octreotide (Octreotide Acetate) worldwide →
Regulator price references for Octreotide (Octreotide Acetate)
Published list or reimbursement prices for Octreotide (Octreotide Acetate) presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Australia | Sandostatin 0.05 | Injection 50 micrograms (as acetate) in 1 mL | 14.00 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin 0.05 | Injection 50 micrograms (as acetate) in 1 mL | 14.00 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin 0.1 | Injection 100 micrograms (as acetate) in 1 mL | 28.00 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin 0.1 | Injection 100 micrograms (as acetate) in 1 mL | 28.00 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin 0.5 | Injection 500 micrograms (as acetate) in 1 mL | 103.91 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Octreotide (SUN) | Injection 500 micrograms (as acetate) in 1 mL | 103.91 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 10 mg (as acetate), vial and diluent syringe | 394.58 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 10 mg (as acetate), vial and diluent syringe | 394.58 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 10 mg (as acetate), vial and diluent syringe | 394.58 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | 525.31 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | 525.31 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | 525.31 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Sandostatin LAR | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | 603.66 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Austria | Sandostatin 50 mcg/ml Inj.-/Inf.lsg. | 0.05mg/1ml | 5St | 39.60 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Austria | Sandostatin 100 mcg/ml Inj.-/Inf.lsg. | 0.1mg/1ml | 5St | 74.10 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Austria | Sandostatin LAR 10 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | 10mg | 1St | 183.55 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Austria | Sandostatin 500 mcg/ml Inj.-/Inf.lsg. | 0.5mg/1ml | 5St | 282.30 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Austria | Sandostatin LAR 20 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | 20mg | 1St | 291.35 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Austria | Sandostatin LAR 30 mg Plv. u. Lsgm. zur Herst. einer Inj.susp. | 30mg | 1St | 384.90 EUR | KVP (Kassenverkaufspreis) | eEKO (Erstattungskodex) | 2026-09-03 |
| Bahrain | Sandostatin | 0.1mg/1ml | 5 X 1ML | 21.81 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Syngro | 20mg | 1 + 1 | 313.69 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Sandostatin Lar | 20mg | 1 + 1 | 448.32 BHD | retail (max) | NHRA | 2026-09-01 |
| Bahrain | Syngro | 30mg | 1 + 1 | 470.54 BHD | retail (max) | NHRA | 2026-09-01 |
| Greece | SANDOSTATIN INJ.SO.INF 0,1MG/ML AMP BTx5 AMP | 0.1mg/1ml | 6.19 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | SANDOSTATIN INJ.SO.INF 0,5MG/ML AMP BT x 5 AMP x 1ML | 0.5mg/1ml | 41.45 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Okrodin® Pd.s.in.pr 10mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | 10mg+2ml | 133.02 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Okrodin® Pd.s.in.pr 20mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | 20mg+2ml | 165.09 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | SANDOSTATIN LAR PS.INJ.SUS 10MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | 10mg+2ml | 204.65 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | Okrodin® Pd.s.in.pr 30mg/Vial Bt X 1 Unit (1 Glass Vial + 1 P.f.syr X 2 mL Solv + 1 Βελονα Ασφαλειας + 1 Προσαρμογεας Φιαλιδιου) | 2ml+30mg | 224.28 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | SANDOSTATIN LAR PS.INJ.SUS 20MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | 20mg+2ml | 253.98 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Greece | SANDOSTATIN LAR PS.INJ.SUS 30MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου x 2,5 ML SOLV + 1 βελόνα ασφαλείας + 1 προσαρμογέας φιαλιδίου | 2.5ml+2ml+30mg | 345.04 EUR | producer price (ex-factory) | MoH deltio timwn | 2026-09-03 | |
| Iceland | Sandostatin | 0.05mg/1ml | lykjur | 2,238.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Sandostatin | 0.1mg/1ml | lykjur | 3,213.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Octreotid | 0.1mg/1ml | lykjur | 11,050.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Sandostatin Lar | 10mg | hgl | 103,833.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Sandostatin Lar | 20mg | hgl | 113,653.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Sandostatin Lar | 30mg | hgl | 145,004.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Italy | OCTREOTIDE*5 fiale EV SC 0,05 mg 1 ml | 0.05mg | OCTREOTIDE 50MCG 5 UNITA' USO PARENTERALE | 15.99 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | TREOJECT*5 siringhe EV SC 1 ml 50 mcg/ml | 0.05mg | OCTREOTIDE 50MCG 5 UNITA' USO PARENTERALE | 20.00 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SIROCTID*5 siringhe 1 ml 50 mcg/ml | 0.05mg | OCTREOTIDE 50MCG 5 UNITA' USO PARENTERALE | 20.00 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*5 fiale EV SC 0,1 mg/1 ml | 0.1mg | OCTREOTIDE 100MCG 5 UNITA' USO PARENTERALE | 26.80 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,05 mg/ml | 0.05mg | OCTREOTIDE 0,05MG 10 UNITA' USO PARENTERALE | 31.98 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | TREOJECT*5 siringhe EV SC 1 ml 100 mcg/ml | 0.1mg | OCTREOTIDE 100MCG 5 UNITA' USO PARENTERALE | 33.51 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SIROCTID*5 siringhe 1 ml 100 mcg/ml | 0.1mg | OCTREOTIDE 100MCG 5 UNITA' USO PARENTERALE | 33.51 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*1 flaconcino SC 1 mg 5 ml | 1mg | OCTREOTIDE 1MG 1 UNITA' USO PARENTERALE | 50.98 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*1 flaconcino SC EV 5 ml 1 mg/5 ml | 1mg | OCTREOTIDE 1MG 1 UNITA' USO PARENTERALE | 50.99 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,1 mg/ml | 0.1mg | OCTREOTIDE 0,1MG 10 UNITA' USO PARENTERALE | 53.60 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*5 fiale 0,5 mg 1 ml | 0.5mg | OCTREOTIDE 500MCG 5 UNITA' USO PARENTERALE | 143.73 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | TREOJECT*5 siringhe SC EV 1 ml 500 mcg/ml | 0.5mg | OCTREOTIDE 500MCG 5 UNITA' USO PARENTERALE | 143.73 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SIROCTID*5 siringhe SC EV 1 ml 500 mcg/ml | 0.5mg | OCTREOTIDE 500MCG 5 UNITA' USO PARENTERALE | 143.73 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*10 fiale SC EV 1 ml 0,5 mg/ml | 0.5mg | OCTREOTIDE 0,5MG 10 UNITA' USO PARENTERALE | 287.45 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 10 mg + 1 siringa solv 2 ml + adattatore + ago | 10mg | OCTREOTIDE 10MG 1 UNITA' USO PARENTERALE | 498.46 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SANDOSTATINA LAR*1 flacone IM 10 mg + siringa 2 ml + 1 ago | 10mg | OCTREOTIDE 10MG 1 UNITA' USO PARENTERALE | 747.31 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 20 mg + 1 siringa solv 2 ml + adattatore + ago | 20mg | OCTREOTIDE 20MG 1 UNITA' USO PARENTERALE | 859.20 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | OCTREOTIDE*1 flacone polv sosp iniett 30 mg + 1 siringa solv 2 ml + adattatore + ago | 30mg | OCTREOTIDE 30MG 1 UNITA' USO PARENTERALE | 1,116.45 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SANDOSTATINA LAR*1 flacone IM 20 mg + siringa 2 ml + 1 ago | 20mg | OCTREOTIDE 20MG 1 UNITA' USO PARENTERALE | 1,288.15 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Italy | SANDOSTATINA LAR*1 flacone IM 30 mg + siringa 2 ml + 1 adattatore + 1 ago | 30mg | OCTREOTIDE 30MG 1 UNITA' USO PARENTERALE | 1,673.83 EUR | prezzo al pubblico (classe A) | AIFA liste A/H | 2026-09-02 |
| Luxembourg | Sandostatine SOL.INJ. 0,5 mg / 1 mL 1*10 ampoules 1 mL | 0.5mg/1ml | 188.56 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Luxembourg | Sandostatine Long Acting Repeatable PSV.SP.INJ. 20 mg 1*1 flacon poudre + 1*1 ser.prer.solvant | 20mg | 545.66 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| Luxembourg | Sandostatine Long Acting Repeatable PSV.SP.INJ. 30 mg 1*1 flacon poudre + 1*1 ser.prer.solvant | 30mg | 732.93 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| MA | Sandostatine * | 0.05mg | 1 BOITE 6 AMPOULE | 344.00 MAD | PPV (public price) | CNOPS liste des medicaments | 2026-09-05 |
| MA | Sandostatine * | 0.1mg | 1 BOITE 6 AMPOULE | 532.00 MAD | PPV (public price) | CNOPS liste des medicaments | 2026-09-05 |
| MA | Sandostatine * | 0.5mg | 1 BOITE 6 AMPOULE | 2,822.00 MAD | PPV (public price) | CNOPS liste des medicaments | 2026-09-05 |
| Norway | Sandostatin | 1 ml | 227.40 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 | |
| Norway | Sandostatin | 1 ml | 303.30 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 | |
| Norway | Sandostatin LAR | 10mg | 8,594.20 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 | |
| Norway | Sandostatin LAR | 20mg | 10,791.20 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 | |
| Norway | Sandostatin LAR | 30mg | 13,752.20 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 | |
| Saudi Arabia | Ocran | 133.00 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Sandostatin 0.2mg-mL 5ml Amp | 0.2mg+5ml | 348.35 SAR | public | SFDA | 2026-09-01 | |
| Saudi Arabia | Ocran | 665.00 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Syngro | 1,510.30 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Sandostatin Lar 20mg Vial | 20mg | 5,326.70 SAR | public | SFDA | 2026-09-01 | |
| United Arab Emirates | Sandostatin® 0.1mg/ml | 0.1mg/1ml | 1ml Ampoule x 5's | 284.50 AED | public | EDE | 2026-08-31 |
| United Arab Emirates | Sandostatin®LAR® 20mg | 20mg | 1 Vial of Drug Product + 1 Prefilled Syringe of Vehicle + 1 Safety Injection Needle + 1 Vial adapter | 10,530.00 AED | public | EDE | 2026-08-31 |
Marketed Canadian products with the same active ingredient
| DIN | Product | Company | Strength | Form |
|---|---|---|---|---|
| 02239324 | Sandostatin Lar | Novartis Pharmaceuticals Canada Inc | 20 mg | Powder For Suspension, Sustained-Release |
| 02239325 | Sandostatin Lar | Novartis Pharmaceuticals Canada Inc | 30 mg | Powder For Suspension, Sustained-Release |
Related molecules (ATC H01CB)
- Lanreotide (Lanreotide Acetate)
- Octreotide (Octreotide Acetate)
- Pasireotide (Pasireotide Diaspartate)
- Pasireotide (Pasireotide Pamoate)
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Sandostatin Lar (DIN 02239323) marketed in Canada?
Yes. Health Canada lists DIN 02239323 as Marketed as of 27 Jan 1999.
Who holds the Canadian licence for this product?
Novartis Pharmaceuticals Canada Inc is the company of record in the Health Canada Drug Product Database.
Is Octreotide (Octreotide Acetate) registered outside Canada?
Yes — Nexara Health has matched 386 registrations in 33 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02239323, status date 1999-01-27; national medicine registries: AIFA liste A/H, BDA, CNOPS liste des medicaments, CNS liste positive, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, FEST (DMP), Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NHRA, NPRA, PBS, SUKL DLP, URPL RPL; price sources: AIFA liste A/H, CNOPS liste des medicaments, CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NHRA, PBS, SFDA. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02239323, status date 1999-01-27; national medicine registries: AIFA liste A/H, BDA, CNOPS liste des medicaments, CNS liste positive, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, FEST (DMP), Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NHRA, NPRA, PBS, SUKL DLP, URPL RPL; price sources: AIFA liste A/H, CNOPS liste des medicaments, CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NHRA, PBS, SFDA.
Novartis Pharmaceuticals Canada Inc — company profileWho else makes Octreotide (Octreotide Acetate)All Canadian Octreotide (Octreotide Acetate) productsLanreotide (Lanreotide Acetate)Octreotide (Octreotide Acetate)Pasireotide (Pasireotide Diaspartate)Pasireotide (Pasireotide Pamoate)Sandostatin LarSandostatin Lar
Health Canada Drug Product Database (DPD), DIN 02239323, status date 1999-01-27; national medicine registries: AIFA liste A/H, BDA, CNOPS liste des medicaments, CNS liste positive, eEKO (Erstattungskodex), EMA centrally authorised, EU national register, FEST (DMP), Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, MoH deltio timwn, NHRA, NPRA, PBS, SUKL DLP, URPL RPL; price sources: AIFA liste A/H, CNOPS liste des medicaments, CNS liste positive, DMP (Statens legemiddelverk) maksimalpris, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NHRA, PBS, SFDA. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.